MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the start of a nationwide trial to examine the relationship between the company’s OptiVol® Fluid Status Monitoring technology and the ability to predict worsening heart failure, a leading cause of hospitalizations worldwide. The trial will assess whether more frequent (monthly vs. quarterly) review of patient data results in earlier clinical intervention.
